Chapter 18 · Module 2
Levodopa and Carbidopa
Mechanism, benefits of combination, and clinical profile
Why Levodopa — Not Dopamine
Problem
Dopamine Cannot Enter the Brain
Dopamine is charged and water-soluble
Blocked by blood-brain barrier tight junctions
Systemic dopamine stays in the periphery
No central nervous system effect achieved
Solution
Levodopa Crosses as an Amino Acid
Levodopa is a neutral amino acid — uses large neutral amino acid transporter
Crosses blood-brain barrier into the brain
Converted to dopamine by aromatic amino acid decarboxylase inside the brain
Dopamine replenished at the striatum
What Carbidopa Adds
Mechanism
Carbidopa — Peripheral Aromatic Amino Acid Decarboxylase Inhibitor
Does not cross the blood-brain barrier — acts only in peripheral tissues
Blocks conversion of levodopa to dopamine in the gut, liver, and bloodstream
More levodopa reaches the brain unchanged
No antiparkinsonian effect on its own
Benefit 1
Lower Dose
Required levodopa dose reduced by ~75%
Benefit 2
Less Nausea
Peripheral dopamine at gut and chemoreceptor trigger zone reduced
Benefit 3
Fewer Cardiovascular Effects
Orthostatic hypotension and arrhythmia risk reduced
Key Adverse Effects
Early
Nausea and Orthostatic Hypotension
Reduced but not eliminated by carbidopa
Take with food; start low, titrate slowly
Long-Term
Motor Complications
Wearing-off phenomenon
On-off fluctuations
Dyskinesias (involuntary movements)
Covered in detail — Module 3
Neuropsychiatric
Hallucinations and Psychosis
Mesolimbic dopamine excess
More common in older patients
Nonselective monoamine oxidase inhibitors contraindicated — hypertensive crisis risk